Skip to search boxSkip to navigationSkip to main content

Translumbosacral Neuromodulation Therapy for Fecal Incontinence: A Randomized Frequency Response Trial

  • Satish S.C. Rao(corresponding author)
    ,
  • Xuelian Xiang
    ,
  • Amol Sharma
    ,
  • Tanisa Patcharatrakul
    ,
  • Yun Yan
    ,
  • Rachael Parr
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

INTRODUCTION:Treatments for fecal incontinence (FI) remain unsatisfactory because they do not remedy the underlying multifactorial dysfunction(s) including anorectal neuropathy. The aim of this study was to investigate the optimal dose frequency, clinical effects, and safety of a novel treatment, translumbosacral neuromodulation therapy (TNT), aimed at improving neuropathy.METHODS:Patients with FI were randomized to receive 6 sessions of weekly TNT treatments consisting of 600 repetitive magnetic stimulations over each of 2 lumbar and 2 sacral sites with either 1, 5, or 15 Hz frequency. Stool diaries, FI severity indices, anorectal neurophysiology and sensorimotor function, and quality of life were compared. Primary outcome measure was the change in FI episodes/week. Responders were patients with ≥50% decrease in weekly FI episodes.RESULTS:Thirty-three patients with FI participated. FI episodes decreased significantly (Δ ±95% confidence interval, 4.2 ± 2.8 (1 Hz); 2 ± 1.7 (5 Hz); 3.4 ± 2.5 (15 Hz); P < 0.02) in all 3 groups when compared with baseline. The 1 Hz group showed a significantly higher (P = 0.04) responder rate (91 ± 9.1%) when compared with the 5 Hz group (36 ± 18.2%) or 15 Hz (55 ± 18.2%); no difference was found between the 5 and 15 Hz groups (P = 0.667). Anal neuropathy, squeeze pressure, and rectal capacity improved significantly only in the 1 Hz (P < 0.05) group compared with baseline, but not in other groups. Quality of life domains improved significantly (P < 0.05) with 1 and 5 Hz groups. No device-related serious adverse events were noted.DISCUSSION:TNT significantly improves FI symptoms in the short term, and the 1 Hz frequency was overall better than 5 and 15 Hz. Both anorectal neuropathy and physiology significantly improved, demonstrating mechanistic improvement. TNT is a promising, novel, safe, efficacious, and noninvasive treatment for FI (see Visual Abstract, Supplementary Digital Content 3, http://links.lww.com/AJG/B598).

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 162-170 (9 pages)

Journal (Volume, Issue Number)

American Journal of Gastroenterology (Volume 116, Issue 1)

Publication milestones

  • Published - 01/01/2021

Publication status

Published - 01/01/2021

ISSN

0002-9270

Publication IDs

  • Scopus: 85094603949
  • PubMed: 32740081

Publication metrics

Metrics

SciVal
Author count
8
SciVal
Paper percentile
92
SciVal
Top percentile
10
SciVal
citations
1
Fractional count
3
Fractional count
0.38
Fractional count
5
Fractional count
0.63
Fractional count
3
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
36
Citation count
35
Mentions
5

Funding Details

Financial support: This study was supported by NIH—5R21 DK104127-02.
FundersFunding number
NIH
-
NIDDK
R21DK104127